Mariner LLC Buys 8,107 Shares of Sanofi (NASDAQ:SNY)

Mariner LLC increased its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 8.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 108,997 shares of the company's stock after purchasing an additional 8,107 shares during the quarter. Mariner LLC's holdings in Sanofi were worth $5,257,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Barclays PLC raised its stake in shares of Sanofi by 58.3% during the fourth quarter. Barclays PLC now owns 1,012,927 shares of the company's stock valued at $48,853,000 after acquiring an additional 373,155 shares during the last quarter. SageView Advisory Group LLC acquired a new position in Sanofi during the 4th quarter worth about $300,000. Sagespring Wealth Partners LLC bought a new stake in shares of Sanofi in the 4th quarter valued at about $469,000. Townsquare Capital LLC grew its position in shares of Sanofi by 10.0% in the 4th quarter. Townsquare Capital LLC now owns 31,061 shares of the company's stock valued at $1,498,000 after buying an additional 2,813 shares during the last quarter. Finally, Crux Wealth Advisors acquired a new stake in shares of Sanofi in the fourth quarter valued at about $308,000. 14.04% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have commented on SNY. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. BNP Paribas initiated coverage on Sanofi in a report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 target price for the company. Finally, The Goldman Sachs Group began coverage on Sanofi in a research note on Friday, March 21st. They issued a "neutral" rating and a $65.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $63.33.

Sanofi Stock Down 1.4 %

Shares of SNY traded down $0.74 during trading hours on Friday, hitting $52.80. The stock had a trading volume of 3,128,154 shares, compared to its average volume of 2,379,700. Sanofi has a 1-year low of $45.80 and a 1-year high of $60.12. The firm has a market capitalization of $133.38 billion, a P/E ratio of 21.21, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. The firm has a 50 day simple moving average of $54.56 and a 200-day simple moving average of $52.11. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating analysts' consensus estimates of $0.90 by $0.04. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The firm had revenue of $10.41 billion during the quarter, compared to analysts' expectations of $9.79 billion. Sell-side analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Increases Dividend

The firm also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be issued a dividend of $2.0369 per share. This is an increase from Sanofi's previous annual dividend of $1.48. The ex-dividend date of this dividend is Friday, May 9th. This represents a yield of 3.1%. Sanofi's dividend payout ratio is presently 64.26%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.